"Pyrrolidinones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of compounds that are derivatives of oxo-pyrrolidines. A member of this group is 2-oxo pyrrolidine, which is an intermediate in the manufacture of polyvinylpyrrolidone. (From Merck Index, 11th ed)
| Descriptor ID |
D011760
|
| MeSH Number(s) |
D03.383.773.812
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pyrrolidinones".
Below are MeSH descriptors whose meaning is more specific than "Pyrrolidinones".
This graph shows the total number of publications written about "Pyrrolidinones" by people in this website by year, and whether "Pyrrolidinones" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2008 | 1 | 1 | 2 |
| 2009 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2017 | 3 | 1 | 4 |
| 2019 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
| 2025 | 1 | 1 | 2 |
| 2026 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pyrrolidinones" by people in Profiles.
-
Tulane virus protease as a structural surrogate for inhibitor screening of human norovirus proteases. J Virol. 2026 03 24; 100(3):e0217625.
-
Brivaracetam effectiveness and patient-reported outcomes in clinical practice: Data from a 12-month prospective, observational study in the United States. Epilepsy Behav. 2025 Dec; 173:110565.
-
Conformational flexibility is a critical factor in designing broad-spectrum human norovirus protease inhibitors. J Virol. 2025 02 25; 99(2):e0175724.
-
HIV-1 subtype F integrase polymorphisms external to the catalytic core domain contribute to severe loss of replication capacity in context of the integrase inhibitor resistance mutation Q148H. J Antimicrob Chemother. 2022 09 30; 77(10):2793-2802.
-
Serum Metabolomics and Incidence of Atrial Fibrillation (from the Atherosclerosis Risk in Communities Study). Am J Cardiol. 2019 06 15; 123(12):1955-1961.
-
Experimental Evolution of Diverse Strains as a Method for the Determination of Biochemical Mechanisms of Action for Novel Pyrrolizidinone Antibiotics. ACS Infect Dis. 2017 11 10; 3(11):854-865.
-
A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111). Pediatr Blood Cancer. 2017 Nov; 64(11).
-
?2-Adrenergic receptor activation mobilizes intracellular calcium via a non-canonical cAMP-independent signaling pathway. J Biol Chem. 2017 06 16; 292(24):9967-9974.
-
Sembragiline in Moderate Alzheimer's Disease: Results of a Randomized, Double-Blind, Placebo-Controlled Phase II Trial (MAyflOwer RoAD). J Alzheimers Dis. 2017; 58(4):1217-1228.
-
Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells. Neoplasia. 2015 Mar; 17(3):289-300.